Back to search results

Hyaluronidase for Post-Stroke Shoulder Pain

This study is looking at a common problem after a stroke: shoulder pain. Researchers want to see if injections of hyaluronidase, a medication, can help reduce this pain. They will compare it to injections of saline (saltwater), which acts as a placebo (a treatment with no active drug). You might be able to join if you are at least 18 years old, have had a stroke between 3 months and 15 years ago, and have a certain difference in how far you can move your affected shoulder. The study will measure changes in your shoulder muscles using a special MRI scan (T1ρ relaxation times) to see if hyaluronidase is effective. The study is currently unclear on its recruitment status and plans to enroll 68 people.

Study design
This is an interventional study comparing hyaluronidase injections to saline injections in 68 participants. It is designed to see if hyaluronidase can improve shoulder pain after a stroke.
What's involved
You would receive injections of either hyaluronidase or saline. Your shoulder muscles would be measured using T1ρ MRI at the start and up to 7 weeks after your first injection.
Compensation
Not stated in the trial record.
Follow-up
Your T1ρ relaxation times will be measured up to 7 weeks after the first injection.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06718413

Myofascial Dysfunction in Post Stroke Shoulder Pain

Recruiting
PHASE2Ages 18+InterventionalTreatment
Johns Hopkins University
~68 participants
Updated 2026-02-27 on ClinicalTrials.gov
What's tested:hyaluronidase plus salinesaline

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
T1ρ relaxation times (ms) in the treatment group
Measured over Baseline, up to 7 weeks post first injection

Conditions

Stroke

Explore related trials

Stroke

NCT06718413

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Johns Hopkins University

    Baltimore, Marylandstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Ning Cao, MD · PRINCIPAL_INVESTIGATOR · Johns Hopkins University

Who to contact

Ning Cao, MD
[email protected]
718-801-0026
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

age ≥18 years;
hemiparesis from an ischemic or hemorrhagic stroke;
time since cerebral injury 3-180 months prior;
show a difference of more than 10 degrees of passive ER-ROM between non-paretic and paretic shoulders with or without pain
ability to give informed consent and HIPAA authorization, and comply with study protocols;

Exclusion

treatment of spasticity with Botulinum toxin or intrathecal baclofen within the past three months, phenol injections within the past 12 months, or ongoing adjustment of anti-spastic medications;
other neurologic condition that may affect motor response (e.g., Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), MS);
clinically significant cognitive dysfunction with score \<19 on Folstein's Mini Mental Status Examination or positive depression screening on the Patient Health Questionnaire (PHQ)-9;
pregnancy;
known hypersensitivity to hyaluronidase;
standard contraindications for MRI;
have non-musculoskeletal PSSP such as only central pain or chronic regional pain syndrome (CRPS)
any condition that will preclude the patient from completing the protocol as determined by the PI.

What this trial measures

  • T1ρ relaxation times (ms) in the treatment groupBaseline, up to 7 weeks post first injection

    Aim 1: T1ρ relaxation times in the treatment group. The primary endpoint will be change in T1ρ relaxation times on MRI in the shoulder girdle muscles of the paretic side between the baseline visit and 5-7 weeks post-first injection (i.e., post injection follow up at Visit 5/ end of Phase 1).